Buy KPV Tripeptide 10mg | Anti-Inflammatory Research Peptide — Fast , Secure Delivery

Most anti-inflammatory compounds block symptoms after the damage is already done. KPV works upstream — shutting down the inflammatory master switch before the cytokine cascade fires. That upstream action is why researchers studying gut inflammation, skin conditions, and immune signalling keep coming back to this compound.

KPV (Lysine-Proline-Valine) is not a synthetic invention. It is a fragment of the body’s own anti-inflammatory hormone — the three C-terminal amino acids of alpha-melanocyte-stimulating hormone (α-MSH), the minimum sequence required to retain its full anti-inflammatory potency. What makes KPV stand apart from almost every other research peptide is its oral bioactivity. It survives gastric digestion. It crosses the intestinal epithelium intact via the PepT1 transporter. It reaches inflamed gut tissue in its active form without injection. For IBD and gut inflammation research, that property changes the entire experimental design.

Get research-grade KPV from PeptideNexusLab — 10mg per vial, ≥99% purity, COA included, fast global shipping.

What Is KPV?

KPV — full name Lysine-Proline-Valine, sequence Lys-Pro-Val — is a naturally derived tripeptide occupying positions 11 through 13 of alpha-melanocyte-stimulating hormone (α-MSH). It was identified when researchers studying α-MSH discovered that this three-residue C-terminal fragment preserved virtually all of the parent hormone’s anti-inflammatory activity — while entirely lacking the sequences responsible for pigmentation, appetite regulation, and arousal effects.

That separation is the key insight. α-MSH is a powerful anti-inflammatory molecule, but its full receptor-binding profile creates confounding variables in research protocols — pigmentation responses, appetite changes, reproductive effects. KPV strips all of that away. What remains is a clean, selective, potent anti-inflammatory signal in a 341 Da tripeptide small enough to be absorbed orally.

KPV is not a melanocyte-stimulating peptide. It does not cause tanning. It does not affect appetite or sexual function. It works through a completely different pathway — entering cells and directly inhibiting NF-κB nuclear translocation, the master switch controlling production of TNF-α, IL-1β, IL-6, and IL-8. This intracellular, upstream mechanism distinguishes it from compounds that merely mop up cytokines after they have already been produced.

Mechanism of Action

NF-κB nuclear translocation inhibition

KPV’s primary and most well-documented mechanism is direct inhibition of NF-κB — the transcription factor that controls production of the major pro-inflammatory cytokines. KPV enters cells and competes with importin-α3, the protein responsible for shuttling the NF-κB p65 subunit into the nucleus. By blocking this translocation step, KPV prevents inflammatory gene transcription at the source — before TNF-α, IL-1β, and IL-6 are ever produced. This is upstream suppression, not downstream clean-up.

NLRP3 inflammasome inhibition

KPV inhibits the NLRP3 inflammasome — the multiprotein trigger that drives the self-perpetuating inflammatory cycle characteristic of chronic gut conditions including ulcerative colitis and Crohn’s disease. NLRP3 activation leads to caspase-1 firing, IL-1β and IL-18 release, and pyroptotic cell death. KPV interrupts this loop at the source — and this mechanism is additive to its NF-κB suppression, meaning two independent inflammatory pathways are addressed simultaneously.

MAPK pathway modulation

KPV modulates the MAPK (mitogen-activated protein kinase) signalling cascade — a second major inflammatory pathway running parallel to NF-κB. A 2025 study confirmed KPV mitigates inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway simultaneously in keratinocyte models. Dual-pathway suppression through two independent molecular routes explains the consistently strong effect sizes observed in preclinical models.

Macrophage M1 to M2 polarisation

KPV shifts macrophage phenotype from M1 (pro-inflammatory, tissue-destructive) to M2 (reparative, anti-inflammatory) — without globally suppressing immune function. This matters because M1-dominant macrophage populations perpetuate chronic inflammation even when the original trigger is gone. M2-polarised macrophages actively participate in tissue resolution and repair. KPV drives this shift while leaving the immune system’s infection-fighting capacity intact — a property that distinguishes it from conventional immunosuppressants.

Melanocortin receptor activation (MC1R / MC3R)

As a fragment of α-MSH, KPV retains binding affinity for melanocortin receptors MC1R and MC3R expressed on immune cells, skin cells, and gut epithelium. Activation of these receptors initiates a receptor-mediated anti-inflammatory signal that complements KPV’s intracellular NF-κB activity. MC1R expression in keratinocytes and dermal immune cells underpins KPV’s research relevance for skin inflammation and wound healing.

PepT1 transporter oral absorption

KPV’s three-amino-acid structure makes it a natural substrate for PepT1 (SLC15A1) — the proton-coupled oligopeptide transporter expressed in intestinal epithelial cells that normally handles dietary di- and tripeptides. This transporter carries KPV across the intestinal wall intact, delivering it to the lamina propria where gut immune cells reside. This is the mechanistic basis for KPV’s oral bioactivity — a property almost no other research peptide shares. Oral administration on an empty stomach minimises PepT1 competition from dietary peptides and maximises uptake.

Research Evidence

Inflammatory bowel disease and ulcerative colitis

The most robust and reproducible preclinical evidence for KPV concerns gut inflammation. Multiple studies using DSS-induced colitis models in rodents have demonstrated that orally administered KPV significantly reduces colonic inflammation, improves disease activity indices, and — critically — restores the tight junction proteins ZO-1, Claudin-5, and Occludin-1 that maintain gut mucosal barrier integrity. In IBD, breakdown of these tight junctions allows bacterial translocation into the gut wall, perpetuating the inflammatory loop. KPV addresses this root structural mechanism, not just surface-level inflammation.

KPV has been shown to exert a stronger anti-inflammatory effect than the full-length α-MSH molecule in several colitis models — a counterintuitive finding that has been reproduced across multiple independent research groups.

Advanced delivery research has demonstrated that a nanoparticle-based KPV conjugate achieved 3.8-fold greater colonic accumulation compared to free KPV, with superior efficacy at a 20-fold lower dose — pointing toward significant translational development potential for targeted gut delivery systems.

Skin inflammation and wound healing

KPV suppresses NF-κB and MAPK activity in keratinocytes and local dermal immune cells, producing anti-inflammatory effects in contact hypersensitivity and atopic dermatitis models. A corneal wound healing study demonstrated topical KPV applied four times daily produced significantly smaller wounds after four days versus controls, alongside direct stimulation of corneal epithelial cell cultures — evidence of both anti-inflammatory and structural repair activity in the same model.

A 2025 study confirmed that KPV at 50 µg/mL restored keratinocyte viability and reduced IL-1β secretion in human keratinocytes exposed to fine particulate matter — one of the most mechanistically detailed and recent pieces of evidence for KPV’s skin-protective activity.

Antimicrobial properties

Research published in the Journal of Leukocyte Biology demonstrated that even low concentrations of KPV reduced the viability of Staphylococcus aureus and Candida albicans — two pathogens responsible for a significant global burden of wound and skin infections. The critical finding was that this antimicrobial activity occurs without suppressing overall immune function, unlike most conventional anti-inflammatory compounds. The researchers noted the dual anti-inflammatory and antimicrobial activity could be particularly useful for conditions where infection and inflammation coexist — chronic wounds, infected eczema, and inflammatory skin conditions with secondary bacterial colonisation.

Vascular inflammation

In 2024, KPV was combined with rapamycin to form carrier-free nanoparticles studied for vascular calcification therapy — a condition with no currently established treatment — through simultaneous regulation of inflammation and autophagy. KPV’s contribution was anti-inflammatory pathway suppression via NF-κB, demonstrating research relevance extending well beyond gut and skin applications.

Dosing Protocols — Preclinical Research Reference

⚠️ The following is drawn entirely from published animal studies and preclinical research protocols. No completed human clinical trial data exists for KPV. This is provided for research planning and educational reference only. PeptideNexusLab does not recommend or endorse human self-administration.

Oral (gut-targeted research)

This is the most researched and preclinically supported route for IBD and gut inflammation models.

• Research dose range: 200–500 mcg, once or twice daily
• Timing: Administered on an empty stomach — reduces PepT1 competition from dietary peptides
• Cycle length in animal models: 14–30 days continuous
• Most referenced stack: KPV 200–500 mcg oral + BPC-157 250–500 mcg oral for synergistic gut mucosal repair

Subcutaneous injection (systemic inflammation research)

Used when systemic rather than gut-localised anti-inflammatory effects are the research objective.

• Research dose range: 100–500 mcg daily
• Frequency: Once daily in most published protocols
• Administration: Standard subcutaneous injection technique using U-100 insulin syringes

Topical (skin and wound healing research)

• Concentration range studied: 0.01–0.1% compounded solution or cream
• Application: Direct application to target tissue
• Evidence basis: Corneal wound healing models, contact hypersensitivity studies, keratinocyte culture experiments

Reconstitution Guide

What you need

Step-by-step reconstitution

Step 1 — Remove the vial from cold storage 10–15 minutes before starting. Allow it to reach room temperature naturally before opening.

Step 2 — Wipe the rubber stopper with a 70% IPA swab. Wait 30 seconds for it to fully dry. Repeat this step every single time you access the vial — not just the first time.

Step 3 — Draw your target BAC water volume into the syringe. Insert the needle at an angle so the water runs slowly down the inner glass wall of the vial — not directly onto the powder. This prevents foaming and mechanical stress on the peptide.

Step 4 — Swirl the vial gently between your palms in a circular motion for 2–3 minutes. Do not shake. Shaking disrupts peptide structure. Swirl until you have a clear, uniform solution with no visible particles.

Step 5 — Inspect the solution. Clear to very slightly pale is normal. Cloudy, discoloured, or particulate — discard and do not use.

Step 6 — Label immediately with reconstitution date and concentration. Refrigerate at 2–8°C. Use within 28 days. Keep away from direct light between uses.

Standard concentration reference

Add 2 mL bacteriostatic water to a 10 mg vial → 5,000 mcg/mL solution. A 500 mcg research dose = 0.10 mL = 10 units on a U-100 insulin syringe. KPV is dosed in micrograms — when stacking with peptides dosed in milligrams such as BPC-157 or TB-500, label every vial clearly to avoid errors.

KPV Stacking Protocols

KPV + BPC-157 — gut repair stack

The most widely referenced KPV combination in the preclinical literature. BPC-157 drives structural gut mucosal repair through VEGF upregulation and growth hormone receptor pathways. KPV suppresses the upstream NF-κB and NLRP3 inflammatory signalling that prevents that repair from holding. The two mechanisms are additive — BPC-157 rebuilds the architecture; KPV quiets the inflammatory environment continuously destroying it.

Typical research protocol: KPV 200–500 mcg oral + BPC-157 250–500 mcg oral or subcutaneous, once daily.

KPV + GHK-Cu — skin inflammation and wound healing stack

GHK-Cu stimulates collagen synthesis, fibroblast activity, and angiogenesis in wound healing models. Combined with KPV’s NF-κB suppression and antimicrobial properties, this combination addresses both the inflammatory phase and the proliferative repair phase of skin healing. Applied topically or subcutaneously depending on the research model.

KPV + TB-500 — systemic anti-inflammatory stack

TB-500’s actin-regulating, cell-migration-promoting properties combined with KPV’s NF-κB and NLRP3 suppression covers both structural repair and immune signalling aspects of inflammation-driven tissue damage — used in broader systemic inflammatory condition research models.

Storage Guide

Vial Specifications

Global Regulatory Status

United States — Not FDA-approved for any indication. Under FDA Pharmacy Compounding Advisory Committee (PCAC) review scheduled for 23 July 2026 for wound healing and inflammatory conditions — a positive outcome would provide clearer regulatory standing for compounded KPV under Section 503A. Available for qualified laboratory research use only.

United Kingdom — Not a controlled substance under the Misuse of Drugs Act 1971. Not licensed by the MHRA. Legal to purchase for bona fide laboratory research.

European Union — Not approved by the EMA. Research chemical status applies across member states; human administration not approved.

Australia — Not listed on the ARTG. Available as a research chemical; TGA has not approved human use.

Canada — Not scheduled under the CDSA. Available for legitimate laboratory research.

WADA — Not currently listed on the WADA Prohibited List as of 2026. Athletes subject to anti-doping regulations should monitor for updates as the melanocortin peptide class receives increasing regulatory attention.

Frequently Asked Questions

What is KPV peptide used for in research? KPV is studied for its anti-inflammatory properties — particularly in models of inflammatory bowel disease, ulcerative colitis, skin inflammation, wound healing, and immune modulation. Its oral bioactivity in animal models makes it one of the most practically distinct compounds in the recovery and healing peptide category.

Does KPV cause pigmentation or tanning? No. KPV lacks the receptor-binding sequence responsible for pigmentation effects. It is not a melanocyte-stimulating peptide and has no structural similarity to compounds like Melanotan-II. Its MC1R interaction is anti-inflammatory, not pigmentation-driving.

How does KPV compare to BPC-157 for gut research? They work through different and complementary mechanisms. BPC-157 drives structural repair of the gut mucosal wall through VEGF and growth hormone receptor pathways. KPV works upstream at the immune-signalling level — suppressing NF-κB and NLRP3, the inflammatory cascades that are actively destroying gut tissue. Together they are the most referenced gut-focused peptide combination in the preclinical literature.

Can KPV be taken orally in research protocols? In animal models, yes. KPV’s tripeptide size allows it to survive gastric degradation and be absorbed via the PepT1 intestinal transporter. This makes oral administration the most studied route for gut inflammation research and is one of the properties that distinguishes KPV from the majority of injectable-only research peptides.

Does KPV suppress the immune system? No — and this distinction matters for research design. KPV selectively suppresses pro-inflammatory signalling through NF-κB and NLRP3 without broadly suppressing immune function. It also demonstrates antimicrobial activity against Staphylococcus aureus and Candida albicans, unlike conventional anti-inflammatory drugs which typically reduce infection-fighting capacity. The immune system’s pathogen response remains intact.

What is the 2026 FDA status of KPV? KPV is scheduled for FDA Pharmacy Compounding Advisory Committee review on 23 July 2026, specifically for wound healing and inflammatory conditions. The committee will evaluate it for the Section 503A Bulk Drug Substances List. A positive outcome would give compounding pharmacies and clinicians clearer regulatory standing. Until the review concludes, researchers should be aware of potential access uncertainty in compounding contexts in the US.

How does KPV compare to conventional IBD treatments? Unlike drugs currently used for IBD such as corticosteroids and immunosuppressants, KPV is a naturally derived tripeptide without significant toxicity signals in preclinical models. Its anti-inflammatory mechanism is intracellular and upstream rather than broadly immunosuppressive. No head-to-head human trial comparison exists — this distinction comes from the preclinical model literature.

Is there human trial data for KPV? No completed randomised controlled human trials have been published for KPV as of 2026. All evidence is from cell culture and animal studies. This is the most important limitation to carry into any interpretation of the preclinical data.

⚠️ Research Use Only: KPV is intended strictly for qualified in vitro laboratory research by trained professionals. Not for human or animal consumption. Not evaluated or approved by the FDA, EMA, MHRA, or TGA. Purchasers confirm compliance with all applicable local regulations.